CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
Buparlisib (BKM120)drug
Likely dose
Buparlisib (BKM120) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02301364
NCT02301364Phase 2Completed
CompareCT.gov

A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Memorial Sloan Kettering Cancer Center·interventional·Posted Nov 25, 2014·Updated Oct 19, 2017

In Brief

A Phase 2 clinical trial evaluating Buparlisib (BKM120) for Lymphoma and 2 related conditions. Completed, enrolled 4 participants across 4 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 25, 2014
Enrollment StartNov 20, 2014
Primary CompletionOct 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.6 years ago

Interventions

Buparlisib (BKM120)drug

Buparlisib 100 mg once daily.